Assetmark, Inc Biomarin Pharmaceutical Inc Transaction History

Assetmark, Inc

$34.9 Billion
Q3 2024

A detailed history of Assetmark, Inc transactions in Biomarin Pharmaceutical Inc stock. As of the latest transaction made, Assetmark, Inc holds 332 shares of BMRN stock, worth $22,121. This represents 0.0% of its overall portfolio holdings.

Number of Shares

332

Previous 21,043 98.42%

Holding current value

$22,121

Previous $1.73 Million 98.67%

% of portfolio

0.0%

Previous 0.01%

29 transactions

Quarter	Operation	Price Per share	shares change	shares Held
Q3 2024 Nov 01, 2024	SELL	$69.02 - $93.84 $1.43 Million - $1.94 Million	-20,711 Reduced 98.42%	332 $23,000
Q2 2024 Aug 13, 2024	BUY	$74.43 - $92.22 $423,953 - $525,285	5,696 Added 37.11%	21,043 $1.73 Million
Q1 2024 May 06, 2024	BUY	$83.81 - $99.0 $259,643 - $306,702	3,098 Added 25.29%	15,347 $1.34 Million
Q4 2023 Feb 09, 2024	BUY	$76.22 - $98.51 $483,234 - $624,553	6,340 Added 107.29%	12,249 $1.18 Million
Q3 2023 Oct 27, 2023	BUY	$85.07 - $94.48 $85,325 - $94,763	1,003 Added 20.44%	5,909 $522,000
Q2 2023 Aug 11, 2023	BUY	$86.68 - $100.3 $104,276 - $120,660	1,203 Added 32.49%	4,906 $425,000
Q1 2023 May 05, 2023	BUY	$87.74 - $117.27 $35,446 - $47,377	404 Added 12.25%	3,703 $360,000
Q4 2022 Feb 10, 2023	BUY	$80.93 - $108.63 $84,167 - $112,975	1,040 Added 46.04%	3,299 $341,000
Q3 2022 Nov 01, 2022	BUY	$82.16 - $96.94 $71,643 - $84,531	872 Added 62.87%	2,259 $191,000
Q2 2022 Aug 03, 2022	BUY	$71.48 - $86.85 $72,051 - $87,544	1,008 Added 265.96%	1,387 $115,000
Q1 2022 May 13, 2022	BUY	$74.28 - $92.69 $22,655 - $28,270	305 Added 412.16%	379 $29,000
Q4 2021 Feb 14, 2022	SELL	$71.72 - $91.47 $1,075 - $1,372	-15 Reduced 16.85%	74 $7,000
Q3 2021 Nov 12, 2021	BUY	$74.77 - $85.47 $1,196 - $1,367	16 Added 21.92%	89 $7,000
Q2 2021 Aug 16, 2021	BUY	$75.51 - $84.79 $151 - $169	2 Added 2.82%	73 $6,000
Q3 2020 Nov 13, 2020	BUY	$71.87 - $131.03 $287 - $524	4 Added 5.97%	71 $5,000
Q2 2020 Aug 11, 2020	SELL	$79.55 - $124.22 $159 - $248	-2 Reduced 2.9%	67 $8,000
Q1 2020 May 12, 2020	SELL	$71.37 - $96.85 $214 - $290	-3 Reduced 4.17%	69 $6,000
Q4 2019 Feb 11, 2020	SELL	$64.27 - $86.37 $1,221 - $1,641	-19 Reduced 20.88%	72 $6,000
Q3 2019 Nov 13, 2019	BUY	$67.4 - $85.11 $134 - $170	2 Added 2.25%	91 $6,000
Q2 2019 Aug 14, 2019	SELL	$80.35 - $93.9 $3,053 - $3,568	-38 Reduced 29.92%	89 $8,000
Q1 2019 May 14, 2019	SELL	$84.2 - $98.62 $3,199 - $3,747	-38 Reduced 23.03%	127 $11,000
Q4 2018 Feb 13, 2019	SELL	$80.14 - $106.07 $480 - $636	-6 Reduced 3.51%	165 $14,000
Q3 2018 Nov 13, 2018	BUY	$93.92 - $105.72 $2,441 - $2,748	26 Added 17.93%	171 $17,000
Q2 2018 Aug 01, 2018	BUY	$76.01 - $99.03 $11,021 - $14,359	145 New	145 $14,000
Q1 2018 May 16, 2018	SELL	$77.67 - $92.63 $2,407 - $2,871	-31 Closed	0 $0
Q4 2017 Feb 13, 2018	BUY	$80.76 - $95.13 $1,857 - $2,187	23 Added 287.5%	31 $3,000
Q3 2017 Nov 08, 2017	BUY	$80.6 - $94.95 $322 - $379	4 Added 100.0%	8 $1,000
Q4 2016 Sep 15, 2017	SELL	N/A	-9 Reduced 69.23%	4 $0
Q4 2015 Sep 15, 2017	BUY	N/A	13	13 $1,000

Others Institutions Holding BMRN

# of Institutions

637

Shares Held

177M

Call Options Held

2.01M

Put Options Held

1.28M

View Full List

About BIOMARIN PHARMACEUTICAL INC

Ticker BMRN
Exchange NASDAQ
Sector Healthcare
Industry Biotechnology
Shares Outstandng 185,824,000
Market Cap $12.4B
Description
BioMarin Pharmaceutical Inc. develops and commercializes therapies for people with serious and life-threatening rare diseases and medical conditions. Its commercial products include Vimizim, an enzyme replacement therapy for the treatment of mucopolysaccharidosis (MPS) IV type A, a lysosomal storage disorder; Naglazyme, a recombinant form of N-a...

More about BMRN

Track This Portfolio

Portfolio Update

Get notified when there are updates to the investment portfolio of Assetmark, Inc, based on Form 13F filings with the SEC.

News

Stay updated on Assetmark, Inc with notifications on news.

Account